-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IVWx+tz5QkpBWBv7uXft73Rp2tZb/zeBi4XzefEZXXET41TDQwEGbUJ8XbsTS8v8 Kcn2BaeiwwZswQmxnoQZsw== 0001225208-09-006775.txt : 20090310 0001225208-09-006775.hdr.sgml : 20090310 20090310183803 ACCESSION NUMBER: 0001225208-09-006775 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090306 FILED AS OF DATE: 20090310 DATE AS OF CHANGE: 20090310 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cazala Beatrice J CENTRAL INDEX KEY: 0001457948 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 09670853 BUSINESS ADDRESS: BUSINESS PHONE: 212-549-4429 MAIL ADDRESS: STREET 1: BRISTOL-MYERS SQUIBB COMPANY STREET 2: ROUTE 206 & PROVINCELINE ROAD CITY: LAWRENCEVILLE STATE: NJ ZIP: 08543 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 3 1 doc3.xml X0203 3 2009-03-06 0 0000014272 BRISTOL MYERS SQUIBB CO BMY 0001457948 Cazala Beatrice J BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCELINE ROAD LAWRENCEVILLE NJ 08543 1 Pres Global Comm & Pres Europe Common Stock, $0.10 par value 63477.58 D Option (right to buy) 21.27 2013-03-11 Common Stock, $0.10 par value 32250 D Option (right to buy) 21.88 2017-09-06 Common Stock, $0.10 par value 73501 D Option (right to buy) 24.55 2015-10-04 Common Stock, $0.10 par value 37145 D Option (right to buy) 24.74 2016-11-30 Common Stock, $0.10 par value 100000 D Option (right to buy) 25.45 2015-02-28 Common Stock, $0.10 par value 46667 D Option (right to buy) 27.36 2016-09-11 Common Stock, $0.10 par value 42911 D Option (right to buy) 28.11 2014-03-01 Common Stock, $0.10 par value 40600 D Option (right to buy) 42.64 2010-03-06 Common Stock, $0.10 par value 26817 D Option (right to buy) 48.07 2012-03-04 Common Stock, $0.10 par value 22500 D Option (right to buy) 59.78 2011-03-05 Common Stock, $0.10 par value 19718 D Option (right to buy) 61.09 2010-01-02 Common Stock, $0.10 par value 2524 D Performance Shares Common Stock, $0.10 par value 37010 D Restricted Stock Units Common Stock, $0.10 par value 37840 D Currently Exercisable. 18,375 shares are currently exercisable. 18,375 shares will become exercisable on March 7, 2010, 18375 shares will become exercisable on March 7, 2011 and the remaining 18,376 shares will become exercisable on March 7, 2012. 18,572 shares are currently exercisable. 9,286 shares will become exercisable on April 5, 2009 and the remaining 9,287 shares will become exercisable on April 5, 2010. 33,333 shares will become exercisable on December 1, 2009, 33,333 shares will become exercisable on December 1, 2010 and the remaining 33,334 shares will become exercisable on December 1, 2011. 10,727 shares are currently exercisable. 10,728 shares will become exercisable on March 12, 2009, 10,728 shares will become exercisable on March 12, 2010 and the remaining 10,728 shares will become exercisable on March 12, 2011. Each performance share is converted into one share of common stock upon distribution of the banked shares. Consists of 24,881 performance shares banked under the 2007-2009 Long-Term Performance Award with a payout date during the first quarter of 2010 and 12,129 performance shares banked under the 2008-2010 Regular Long-Term Performance and the 2008-2010 Special Long-Term Performance Awards with a payout date during the first quarter of 2011. Restricted stock units awarded on March 1, 2005 and July 1, 2005 vest one-third on the third, fourth and fifth anniversaries of the grant date. Restricted stock units awarded on April 5, 2006, March 12, 2007 and March 7, 2008 vest 25% on the first, second, third and fourth anniversaries of the grant date. Shares are converted into shares of common stock upon vesting. Each restricted stock unit converts into one share of common stock upon vesting. cazala.TXT /s/ Sonia Vora, Attorney-in-Fact 2009-03-10 EX-24 2 cazala.txt POWER OF ATTORNEY I, Beatrice J Cazala, President, Global Commericalization and President, Europe of Bristol-Myers Squibb Company, a corporation duly organized and existing under the laws of the State of Delaware, in the United States of America, and having its principal place of business at 345 Park Avenue, New York, New York, do hereby constitute and appoint each of Anne Nielsen, Sonia Vora and Katherine Kelly, individually,as my lawful attorney-in-fact and in my name, place and stead to execute and deliver any and all documents relating to insider reporting requirements under Section 16 of the Securities Exchange Act of 1934, including, without limitation, the execution and filing of all Forms 3, 4 and 5, and to take such other action, as such attorney considers necessary or appropriate, to effectuate such transactions until such time as I am no longer an officer of Bristol Myers Squibb Company. IN WITNESS WHEREOF, I have executed this Power of Attorney on this 4th day of March 2009. /s/ Beatrice J Cazala Beatrice J Cazala -----END PRIVACY-ENHANCED MESSAGE-----